|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fatty liver index (FLI), which is calculated by the equation comprising waist circumference, body mass index (BMI), triglyceride, and gamma glutamyl transpeptidase (GGT), is frequently used for hepatic steatosis evaluation.
|
30981560 |
2020 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hp 2-2 patients treated with VitE versus placebo showed significant histologic improvement (51% vs. 20%; OR=4.2; P=0.006), resolution of steatohepatitis (44% vs. 12%; OR=6.2; P=0.009), decrease in nonalcoholic fatty liver disease Activity Score (NAS) (-2.2 vs. -0.6; P=0.001), and decrease in liver enzymes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase.
|
30586008 |
2020 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was a significant reduction in body mass index (median change, Δ = -0.7 kg per m<sup>2</sup>, p = 0.011), waist circumference (Δ = -3 cm, p = 0.033), systolic blood pressure (Δ = -9 mmHg, p = 0.024), diastolic blood pressure (Δ = -6 mmHg, p = 0.033), fasting blood glucose (Δ = -1.7 mmol/L, p = 0.008), total cholesterol (Δ = -0.5 mmol/L, p = 0.011), gamma glutamyl transpeptidase (Δ = -19 U/L, p = 0.013), volumetric liver fat fraction (Δ = -7.8%, p = 0.017), steatosis (Δ = -1, p = 0.014), ballooning (Δ = -1, p = 0.034), and fibrosis (Δ = 0, p = 0.046).
|
30684076 |
2020 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate analysis revealed that higher age, female, lower body mass index (BMI), higher serum albumin, lower alanine aminotransferase (ALT), lower gamma-glutamyl transpeptidase, lower total bilirubin, lower α-fetoprotein, lower skeletal muscle attenuation, and liver steatosis were significantly associated with skeletal muscle volume loss.
|
29486094 |
2018 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High BMI (OR = 1.369, P < .001), high diastolic blood pressure (OR = 1.048, P < .001), and high gamma glutamyl transpeptidase (OR = 1.018, P = .009) were independent risk factors for liver steatosis among T2DM patients.This study suggested risk factors screening of liver fibrosis and steatosis.
|
30212992 |
2018 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After 24 weeks, body weight, hemoglobin A1c (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase, body fat mass, and steatosis were significantly decreased compared to baseline measurements in patients with NASH.
|
30234161 |
2018 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ezetimibe significantly reduced serum aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels, and hepatic steatosis and hepatocyte ballooning.
|
28257594 |
2017 |
|
Steatohepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rs12979860 TT or rs8099917 GG genotypes as well as markers of serum and hepatocyte iron overload associated with higher activity of gamma-glutamyl transpeptidase and liver steatosis.
|
27125837 |
2017 |
|
Steatohepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the rare CPT1b 66V (rs3213445) allele had significantly higher γ-glutamyl transpeptidase (GGT), glutamic oxaloacetic transaminase (GOT) and glutamic pyruvate transaminase (GPT) activities (P< 0·0001, P= 0·03 and P= 0·048, respectively) and a higher fatty liver index (FLI, P= 0·026).
|
22809552 |
2013 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using multivariate logistic regression, only increased γ-glutamyl transpeptidase (P = 0.0009) predicted steatosis whereas HOMA-IR (P = 0.0046) predicted NASH.
|
23059409 |
2013 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This association was subsequently replicated for other HCV genotypes and has been linked to spontaneous eradication of HCV, development of steatosis and biochemical changes (such as altered levels of γ-glutamyl transpeptidase and LDL).
|
22641049 |
2012 |
|
Steatohepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, coreMM was associated with a higher γ-glutamyl transpeptidase level (P=0.026) as well as more severe liver fibrosis (P=0.027) than coreWW, and patients with aa70 substitution (coreMW) were associated with more severe liver steatosis and fibrosis than those without (P=0.020 and P=0.002, respectively).
|
21447872 |
2011 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transaminase activities, γ-glutamyl-transpeptidase, serum ferritin levels, homeostasis model assessment of insulin resistance index, and substitutions of amino acid 70 were significantly associated with the presence of steatosis, upon univariate analysis.
|
21054524 |
2011 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The presence of steatosis was independently associated with a higher body mass index, higher levels of gamma-glutamyl transpeptidase and triglyceride, and a higher fibrosis stage.
|
19789836 |
2010 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.
|
20537997 |
2010 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mean serum level of cholesterol, triglyceride, glucose, and gamma-glutamyl transpeptidase as well as the mean body mass index, viral load, stage of fibrosis and frequency of genotype 3 were significantly higher in the patients with than those without steatosis (p < 0.05).
|
18287796 |
2008 |